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Abstract
Background:  There are different factors that influence treatment outcome after ovarian
stimulation and timed-intercourse or intrauterine insemination (IUI). After patient age, it has been
suggested that timing of insemination in relation to ovulation is probably the most important
variable affecting the success of treatment. The objective of this study is to study the value of human
chorionic gonadotropin (hCG) administration and occurrence of luteinizing hormone (LH) surge
in timing insemination on the treatment outcome after follicular monitoring with timed-intercourse
or intrauterine insemination, with or without ovarian stimulation.
Methods: Retrospective analysis of 2000 consecutive completed treatment cycles (637 timed-
intercourse and 1363 intrauterine insemination cycles). Stimulation protocols included clomiphene
alone or with FSH injection, letrozole (an aromatase inhibitor) alone or with FSH, and FSH alone.
LH-surge was defined as an increase in LH level ≥200% over mean of preceding two days. When
given, hCG was administered at a dose of 10,000 IU. The main outcome was clinical pregnancy rate
per cycle.
Results: Higher pregnancy rates occurred in cycles in which hCG was given. Occurrence of an LH-
surge was associated with a higher pregnancy rate with clomiphene treatment, but a lower
pregnancy rate with FSH treatment.
Conclusions:  hCG administration is associated with a favorable outcome during ovarian
stimulation. Awaiting occurrence of LH-surge is associated with a better outcome with CC but not
with FSH treatment.
Background
Ovarian stimulation with timed-intercourse or intrauter-
ine insemination (IUI) has been empirically applied
alone or in combination for treatment of unexplained
infertility, male-factor infertility, anovulatory infertility as
well as other cases of infertility. This treatment modality is
used when the female partner has at least one open tube
in addition to some ovarian function and the male part-
ner has motile sperm [1]. In infertile couples meeting the
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above criteria, combining ovarian stimulation with IUI is
an effective means of achieving pregnancy [2,3].
There are different factors that influence treatment out-
come after ovarian stimulation and timed-intercourse or
IUI [4,5]. These include women's age, ovarian stimulation
protocol, semen parameters and method of semen prepa-
ration [6-8], number of inseminations [9,10] as well as
number of preovulatory follicles, length and cause of
infertility and number of prior treatment cycles [11,12].
Another important factor is timing of intercourse or
insemination. It has been suggested that timing of insem-
ination in IUI cycles in relation to ovulation is probably
the most important variable affecting the success of treat-
ment [3].
With the introduction of IUI into infertility management,
timing of insemination was initially based on past cycle
length and basal body temperature charts [13]. Later, tim-
ing insemination according to LH-surge was found to be
associated with improved outcome [14]. However, with
the development of human chorionic gonadotropin
(hCG) and its application to trigger ovulation and time
insemination, controversy has arisen as to the best
method of timing intercourse or IUI to achieve optimal
pregnancy rates. There is no consensus whether timing of
insemination by waiting for detection of LH-surge, or by
administering hCG without waiting for LH-surge, or by
waiting for LH-surge and then adding hCG, leads to the
best pregnancy rates [15-20].
In this study we looked at treatment outcome (achieve-
ment of clinical pregnancy) according to the three differ-
ent methods of timing intercourse and insemination
currently applied in infertility practice: 1-hCG administra-
tion without waiting for LH-surge, 2-waiting for LH-surge
plus hCG administeration, or 3-waiting for LH-surge
without administering hCG.
Methods
Approval was obtained from the Research Ethics Board of
University of Toronto and Mount Sinai Hospital to review
charts of infertile couples who underwent cycle monitor-
ing for timed-intercourse or IUI. The study was conducted
at Reproductive Biology Units (RBU) located at Toronto
General Hospital before mid-2000 and at Mount Sinai
Hospital after mid-2000, and at Toronto Center for
Advanced Reproductive Technology (TCART). These clin-
ics are academic tertiary referral centers affiliated with
Reproductive Sciences Division, Department of Obstetrics
and Gynecology, University of Toronto, Canada. Charts
were reviewed for treatment cycles completed between
January 1997 and March 2001. The same clinical team
including five reroductive endocrinologists work in both
centers (RBU and TCART) applied the same ovarian stim-
ulation protocols with similar management and follow up
plans in both centers.
This retrospective study included 2000 consecutive com-
pleted treatment cycles (637 timed-timed-intercourse
cycles and 1363 IUI cycles) in 860 infertile women, 250
with polycystic ovarian syndrome (PCOS) and 610 with
unexplained infertility. PCOS was diagnosed according to
the National Institutes of Health consensus criteria [21]
and unexplained infertility was diagnosed by exclusion of
tubal factor infertility (hysterosalpingography and lapar-
oscopy), anovulation (by luteal phase progesterone > 5
nM) and male factor by semenalysis according to WHO
criteria [22].
Criteria for patient inclusion included completed cycles in
which there was only one infertility factor (PCOS or unex-
plained infertility) with comparable semen parameters
meeting the minimum WHO criteria as explained above.
Stimulation protocols included clomiphene citrate (CC)
alone (771 cycles) or with FSH injection (132 cycles),
letrozole (an aromatase inhibitor) alone (146 cycles) or
with FSH (143 cycles), FSH alone (515 cycles). LH-surge
was defined as an increase in LH level ≥200% over mean
of preceding two days LH levels. When given, hCG was
administered at a dose of 10,000 IU, single subcutaneous
or intramuscular injection (Profasi®, Serono, Oakville,
Ontario, Canada or Pregnyl®, Organon, Scarborough,
Ontario, Canada, respectively). All cycles received luteal
phase support with progesterone in the form of vaginal
suppositories 100 mg twice daily. In 293 treatment cycles,
patients received no ovarian stimulation before timed-
intercourse or insemination.
CC was given orally at a dose of 50–100 mg daily from
day 3 to day 7 of menstrual cycle. The aromatase inhibi-
tor, letrozole, was given orally at a dose of 2.5 mg daily
from day 3 to day 7 of menstrual cycle as previously
described for ovulation induction [23-25]. FSH injections
were given in the form of highly purified FSH (Fertinorm®,
Serono, Oakville, Ontario, Canada) or recombinant FSH,
(Gonal-F® Serono, Oakville, Ontario, Canada or Puregon®,
Organon, Scarborough, Ontario, Canada) at a dose of 50–
300 IU/day. When given alone, FSH injections started on
day 3 of menstrual cycle. When given in conjunction with
CC or letrozole, injections started on day 7 of menstrual
cycle.
The managing physician decided the choice of the ovarian
stimulation protocol with the patient based on her clini-
cal profile (mainly the age, duration of infertility and
prior treatment history). An algorithm usually is followed
starting with a natural cycle (no treatment in unexplained
infertility) followed by ovarian stimulation withReproductive Biology and Endocrinology 2004, 2:55 http://www.rbej.com/content/2/1/55
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clomiphene citrate. When pregnancy is not achieved after
about three cycles of clomiphene or if a thin
endometrium is seen, the clomiphene is considered failed
and then the aromatase inhibitor or FSH (alone or in
combination with clomiphene or aromatase inhibitor,
empirically decided) was used.
The development of ovarian follicles was monitored by
transvaginal ultrasound measurement of mean follicular
diameter and serial assays serum LH and estradiol levels.
This was done on a daily basis during the last few days of
stimulation immediately before insemination and less
frequently in the early part of follicular phase. hCG
(10,000 IU) was given to trigger ovulation when mean
diameter of an average of two ovarian follicles was ≥18
mm. IUI was done 38 hours after hCG administration if
no LH-surge occurred. If LH-surge was detected, IUI was
done on the following day and at 38 hours. Intercourse
was recommended exactly like IUI. Patients called to con-
firm the encounter of intercourse on the following day for
documentation.
The decision to give hCG was made by the physician on
call for the infertility unit. The timing of insemination was
based on the achievement of average mean diameter of 18
mm or larger for two or more follicles (one follicle in no-
medication cycles). After reviewing the serum LH level,
the treating physician decided whether an endogenous LH
surge occurred or not. If an endogenous LH surge occurred
a decision was made to give hCG or not based on the phy-
sician preference (no specific guidelines existed). If an LH
surge did not occur, hCG was given to trigger ovulation.
This algorithm of hCG administration contributed to the
homogeneous structure among the different study groups
and absence of significant differences in any of the varia-
bles that might affect the achievement of pregnancy e.g.
age and infertility diagnosis. In the no-medication group,
there was a tendency towards avoiding the use of any
medications to trigger ovulation, often at patient request.
Thus, hCG administration was avoided in most of the
non-stimulated cycles. In the gonadotropin group, there
was a tendency to give hCG to trigger ovulation in most of
the cycles due to general belief among physicians that
hCG is needed because LH-surge achieved during gonado-
tropin stimulation might be inadequate as reviewed by
Macklon and Fauser [26].
The dose and duration of FSH treatment were adjusted
during monitoring of follicular development according to
patient's response including the number of growing folli-
cles and estradiol levels. The goal of ovarian stimulation
was to achieve an average of two ovarian follicles with a
mean diameter of ≥18 mm on the day of hCG
administration.
All insemination cycles included IUI with partner semen.
The same method of semen preparation [sperm wash] was
applied in all insemination cycles. All men had normal
semen analysis by WHO criteria and there was no signifi-
cant difference in the semen parameters of the partners in
the different patients groups as regards sperm number,
motility and strict criteria for morphology (data not
shown). The same 2 infertility nurses performed intrauter-
ine inseminations in all patients.
Pregnancy was diagnosed by quantitative β-hCG two
weeks after timed-intercourse or insemination. Clinical
pregnancy was confirmed by observing fetal cardiac activ-
ity on transvaginal ultrasound four weeks after a positive
pregnancy test.
Intercourse or insemination was timed according to the
administration of hCG, or the occurrence of LH-surge.
Hence there were three study groups: group 1: "hCG-only
group" included cycles in which patients received hCG
[without LH-surge], group 2: "hCG plus LH-surge" group
included cycles in which patients received hCG on the day
of the detected LH-surge, and group 3: "LH-only" group
included cycles in which patients did not receive hCG
[LH-surge occurred].
Two more groups are formed from combinations of the
above three groups. Group 4: "all hCG", include all cycles
in which patients received hCG irrespective to occurrence
of LH-surge [hCG ± LH-surge]. This group is the sum of
groups 1 and 2 [hCG-only group and hCG plus LH
group]. Group 5: all LH-surge group, included all cycles in
which patients had LH-surge whether received hCG or not
[LH ± hCG]. This group is the sum of groups 2 and 3 [hCG
plus LH-surge group and LH-surge-only group]. Box 1
summarizes the five different patients groups.
Group 1: hCG-only group, no LH-surge occurred
Group 2: hCG plus LH-surge group, both hCG was given
and LH-surge occurred on the same day
Group 3: LH-surge-only group, LH-surge occurred but no
hCG was given
Group 4: All hCG group, all cycles in which hCG was
given whether alone or on the day of hCG (sum of groups
1 and 2)
Group 5: All LH-surge group, all cycles in which LH-surge
occurred whether hCG was given or not (sum or groups 2
and 3)Reproductive Biology and Endocrinology 2004, 2:55 http://www.rbej.com/content/2/1/55
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Analysis of data
To look at the effect of hCG administration and ocuur-
rence of LH-surge on the treatment outcome, clinical preg-
nancy rates per cycle were compared among the first three
study groups. To look at the effect of hCG administration
on treatment outcome, clinical pregnancy rates per cycle
were compared between cycles in which hCG was given,
group 4, [hCG alone or with LH-surge] and cycles in
which hCG was not given, group 3 (LH-surge-only
group). Then we confined the comparison on the cycles in
which LH-surge occurred by comparing cycles in which
hCG was given, group 2 (hCG plus LH-surge) with the
cycles in which hCG was not given, group 3 (LH-surge-
only cycles).
To look at the effect of LH-surge on the treatment out-
come we compared all cycles in which LH-surge occurred,
group 5, (whether alone, LH-surge-only or LH-surge plus
hCG cycles) with all cycles in which LH-surge did not
occur, group 1, (hCG-only cycles).
The various factors known to affect the outcome of ovar-
ian stimulation and insemination treatment [4-12,27,28]
including age, number of inseminations, number of prior
treatment cycles (table 1) as well as type of insemination
and infertility diagnosis (table 2) have been compared
among the diferent study groups. There was no statisti-
cally significant difference in any of these variables among
the study groups. There was no significant difference
among the study groups for other important variables that
might have affected the outcome (achievement of preg-
nancy) including the number of follicles, dose of ovarian
stimulation medication (CC and letrozole dose and FSH,
total number of units) as well as estradiol level on the day
of hCG administration. We ran the statistical analysis
applying multiple regression analysis considering the fol-
lowing as important confounding factors: age, number of
prior treatment cycles, infertility diagnosis and insemina-
tion type (intercourse or IUI). When all cycles were con-
sidered together, hCG administration was found to be an
independent factor associated with a higher pregnancy
rate. When sub-grouped according to stimulation type,
the sample size was not large enough with all types of
stimulation to draw the same conclusion although the
trend was maintained for a higher pregnancy rate in asso-
ciation with hCG administration.
Table 1: Various patients characteristics (age, number of treatment cycles and infertility duratin) among the different patients groups. 
Data presented as Mean ± SD (range).
All groups Group 1 
HCG-only
Group 2 hCG 
plus LH-surge
Group 3 
LH-onlysurge only
Group 4 All hCG (sum 
of groups 1 and 2
Group 5 All LH-surge cycles 
Sum of groups 2 and 3
No. of cycles 2000 1146 548 306 1694 854
Age 34.3 ± 4.3 (20–45) 34.2 ± 4.3 (20–45) 34.7 ± 4.1 (24–45) 33.95 ± 4.3 (23–45) 34.36 ± 4.2 (20–45) 34.44 ± 4.2 (23–45)
No. of inseminations 1.1 ± 0.3 (1–2) 1.12 ± 0.32 (1–2) 1.39 ± 0.5 (1–2) 1.24 ± 0.42 (1–2) 1.28 ± 0.45 (1–2) 1.28 ± 0.5 (1–2)
No. of prior 
treatment cycles
2.9 ± 2.2 (1–7) 2.8 ± 2.1 (1–7) 3.1 ± 2.2 (1–6) 2.71 ± 2.4 (1–6) 2.9 ± 2.14 (1–7) 2.96 ± 2.3 (1–6)
There was no statistically signbificant difference among the different groups as regards the age, number of inseminations or prior treatment cycles.
Table 2: The percentage of insemination cycles and infertility diagnosis among the different patients groups. Data are presented as 
number (% from total cycles).
All groups Group 1 
HCG-only
Group 2 hCG plus 
LH-surge
Group 3 
LH-surge-only
Group 4 All hCG (sum 
of groups 1 and 2
Group 5 All LH-surge 
Sum of groups 2 and 3
No. of cycles 2000 1146 548 306 1694 854
IC 637 (31.9%) 364 (31.8%) 157 (28.6%) 116 (37.9%) 521 (30.8%) 273 (32%)
IUI 1363 (68.2%) 782 (68.2%) 391 (71.4%) 190 (62.1%) 1173 (69.2%) 581 (68%)
No. of patients 860 439 315 106 754 421
PCOS 250 (29.1%) 127 (28.9%) 95 (30.2%) 28 (26.4%) 222 (29.4%) 123 (29.2%)
Unexplained infertility 610 (70.9%) 312 (71.1%) 220 (69.8%) 78 (73.6%) 532 (70.6%) 298 (70.8%)
There was no statistically signbificant difference among the different groups as regards the number of timed-intercourse or IUI cycles, or the 
infertility diagnosis.Reproductive Biology and Endocrinology 2004, 2:55 http://www.rbej.com/content/2/1/55
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Statistical analysis
The following statistical tests were used where appropriate
to analyze various data among the study groups: ANOVA
was used to compare between the three groups (hCG
alone, HcG plus LH and LH only groups), Student's t-test,
Chi square test and Bonferroni t-test when comparing
between each two groups (hCG versus no hCG and LH
surge versus no LH surge) in addition to multiple regres-
sion analysis as explained above, considering P value <
0.05 statistically significant. The statistical tests were per-
formed with SigmaStat for Windows Version 1.0 software
(SigmaStat Software HighEdit Professional Copyright®
1993, MicroHelp Inc and HeilerSoftware GmbH, San
Rafael, CA, USA).
Results
Table (3) shows clinical pregnancy rates per cycle among
the three main study groups (hCG-only, hCG plus LH-
surge and LH-surge-only) according to the stimulation
protocols. When all treatment cycles were combined
together, the hCG plus LH-surge group had a significantly
higher clinical pregnancy rate when compared to the
other two groups, hCG-only group (P < 0.05) and LH-
surge-only group (P < 0.01). hCG plus LH-surge group
had a significantly higher clinical pregnancy rate com-
pared to the other two groups in CC treatment cycles.
However, this difference was statistically insignificant
with other ovarian stimulation protocols (CC+FSH,
letrozole, and letrozole + FSH) or the no stimulation
cycles. In FSH treatment cycles, there was a trend for the
hCG-only group to be associated with a higher, though
statistically insignificant, clinical pregnancy rate com-
pared to the other two groups. The same trend was main-
tained when the analysis was done after subgrouping the
cycles acording to type of insemination i.e. timed-inter-
course (figure 1-a) or IUI (figure 1-b). However, the dif-
ferenece was smaller in the IUI cycles. Also, after
subgrouping the patients according to infertility diagnosis
(PCOS or unexplained infertility), the same trend was
maintained (data are not presented).
When all hCG cycles were combined together, the admin-
istration of hCG was associated with higher clinical preg-
nancy rates among all stimulation protocols (figure 2-a).
The difference was statistically significant with CC (P <
0.01), CC + FSH (P < 0.01), and letrozole + FSH treatment
(P < 0.05). To look at the effect of LH-surge on the clinical
pregnancy rate, all cycles in which LH-surge occurred were
compared to the cycles without LH-surge (hCG-only). LH-
surge was associated with a significantly higher pregnancy
rate among the different stimulation protocols that uti-
lized CC, alone or with FSH (P < 0.05). On the other
hand, with FSH treatment (alone or with letrozole), LH-
surge was associated with lower clinical pregnancy rates
that was statistically significant (P < .05) in FSH-only
cycles (figure 2-b).
Discusion
Three important findings of interest arise from results in
this retrospective study. The first is the association of hCG
treatment with higher clinical pregnancy rates irrespective
of stimulation protocol, insemination types (timed-inter-
course or IUI) or infertility diagnoses (PCOS or unex-
plained infertility). The second finding was the trend for a
significantly higher clinical pregnancy rate associated with
LH-surge in CC treatment, either alone or with FSH. This
trend was maintained after sub-grouping according to
insemination type and infertility diagnoses. The third
finding was a significantly lower clinical pregnancy rate
associated with LH-surge in FSH treatment cycles.
To maximize the chance of success, timing of intercourse
and intrauterine insemination should be closely related to
the time of ovulation [1]. Early studies reported discrep-
ancies in the time of ovulation after the onset of LH-surge.
A multicentred collaborative study from the World Health
Organization, found that ovulation occurred 24–56 hours
from the onset of LH-surge and between 8–40 hours after
its peak [29]. Garcia et al, reported that ovulation occurred
after a mean time of 27.3 h from onset of LH-surge [30].
In IVF cycles, oocytes retrieved 36–38 h from the start of
LH-surge achieved good fertilization rates [31]. Nowa-
Table 3: Clinical pregnancy rates per cycle according to method applied for timing insemination or intercourse (hCG-only, hCG plus 
LH-surge or LH-surge-only) among the different ovarian stimulation protocols. Results are expressed as rate (number of pregnancy 
cycles/total number of cycles).
HCG-only (group 1) hCG + LH-surge (group 2) LH-surge-only (group 3) All Cycles
All stimulation cycles 10.2% (109/1068) 14.3% (69/483) 2% (5/256) 10.7% (183/1707)
CC 6.3% (34/539) 15.9% (20/126) 1.9% (2/106) 7.3% (56/771)
CC+FSH 15% (16/108) 30% (6/20) 0 (0/4) 16.7% (22/132)
Letrozole 9% (6/66) 20.3% (14/69) 9% (1/11) 14.4% (21/146)
Letrozole+FSH 17% (14/82) 17.2% (8/58) 0 (0/3) 17.5% (22/143)
FSH 14% (39/273) 10% (21/210) 6.3% (2/32) 12.2% (62/515)
No medication 6.5% (5/78) 12.7% (8/65) 8.8% (13/150) 8.9% (26/293)Reproductive Biology and Endocrinology 2004, 2:55 http://www.rbej.com/content/2/1/55
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days, hCG is used to trigger ovulation and time
insemination which is a common practice among many
infertility centers worldwide. Follicular rupture and ovula-
tion usually occur ~36–48 h after hCG injection [32].
Whether to wait for LH-surge to occur or administer hCG
to trigger ovulation is still a matter of controversy. Mar-
tinez et al [17,33] suggested that a beneficial effect would
occur when the process of natural follicular maturation
Clinical pregnancy rate per cycle among different patients  groups according to method of insemination (timed-inter- course or IUI) Figure 1
Clinical pregnancy rate per cycle among different 
patients groups according to method of insemination 
(timed-intercourse or IUI). A) Clinical pregnancy rate 
per cycle among the different patients groups, timed-inter-
course cycles only. The same pattern was maintained as for 
all cycles combined (timed-intercourse and IUI cycles, table 
3). Higher pregnancy rates were observed in group 2 (hCG + 
LH-surge) when compared to the other two groups: group 1, 
hCG-only (P < 0.05) and group 3, LH-surge-only (P < 0.01). 
Also, all hCG cycles (group 4) was associated with higher 
clinical pregnancy rate when compared to the no hCG i.e. 
LH-surge-only cycles P < 0.01). B) Clinical pregnancy rate 
per cycle among the different patients groups, IUI cycles only. 
The same pattern was maintained as for all cycles (timed-
intercourse and IUI cycles, table 3). Higher pregnancy rates 
were observed in group 2 (hCG + LH-surge) when com-
pared to the other two groups: group 1, hCG-only (not sta-
tistically significant) and group 3, LH-surge-only (P < 0.05). 
Also, all hCG cycles (group 4) was associated with higher 
clinical pregnancy rate when compared to the no hCG i.e. 
LH-surge-only cycles P < 0.05).
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Clinical pregnancy rates according to hCG administeration  and occurrence of LH-surge among different stimulation  protocols Figure 2
Clinical pregnancy rates according to hCG adminis-
teration and occurrence of LH-surge among different 
stimulation protocols. A) Comparison between clinical 
pregnancy rate in cycles in which hCG was given with or 
without an LH-surge versus cycles in which hCG was not 
given (LH-surge alone). Combined intrauterine insemination 
and timed-intercourse cycles, both polycystic ovarian syn-
drome and unexplained infertility patients. Control (Cont), 
clomiphene citrate (CC), FSH (F), and letrozole (Let). B) 
Comparison between clinical pregnancy rates in cycles in 
which an LH-surge occurred (with or without hCG adminis-
tration) versus cycles in which LH-surge did not occur. Com-
bined intrauterine insemination and timed-intercourse cycles, 
both polycystic ovarian syndrome and unexplained infertility 
patients. Control (Cont), clomiphene citrate (CC), FSH (F), 
and letrozole (Let).
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and the spontaneous rise of LH was allowed to occur. In
our study, we found similar findings of a higher clinical
pregnancy rate in the group of hCG plus LH-surge.
However, this improvement in clinical pregnancy rates
was not found when FSH was used alone or with letro-
zole. Of interest, the findings with CC + FSH cycles are
consistent with an earlier report, almost 15 years ago, that
the occurrence of LH-surge was a favorable event, associ-
ated with higher pregnancy and live birth rates in IVF
cycles in which the combination of CC + hMG was
applied for controlled ovarian hyperstimulation [34].
As LH-surge can last for up to 2 days before ovulation in
some patients [35], a treatment plan based on LH-surge
alone can result in inaccurate timing of ovulation and
insemination. When hCG is given before LH-surge there
can be mistiming of follicle maturity. It is therefore rea-
sonable to expect a better pregnancy rate when an ovula-
tory dose of hCG is administered after LH-surge [19].
The occurrence of LH-surge in CC treatment cycles may
indicate a healthy hypothalamo-pituitary axis that has
been released from the estrogen receptor antagonistic
effect of CC and may indicate a rapid clearance of the anti-
estrogenic component of CC. LH-surge, therefore, may
also reflect a lesser peripheral antiestrogen effect at the
level of endometrium and cervix favoring the achieve-
ment of pregnancy.
With FSH treatment, the lower clinical pregnancy rate
associated with LH-surge could be related to premature
timing of LH-surge as a result of rapidly rising estrogen
levels attained during the growth of multiple healthy fol-
licles. This premature LH-surge may result in triggering
the ovulation of immature oocytes. Premature LH-surges
are well-known from experience with controlled ovarian
hyperstimulation for assisted reproduction predating the
use of GnRH analogue pituitary downregulation.
In a similar study design to ours, Awonuga and Govindb-
hai [36] did not find any difference in the pregnancy rate
among the cycles in which hCG was administered or in
which LH-surge occurred. LH-surge detection was,
however, performed with urine kits. Urinary LH monitor-
ing has its limitations that include false-negative results
when peak LH concentrations are low [<40 IU/l]. This has
been found in up to 35% of ovulatory cycles [37]. It is pos-
sible that up to a third of inseminations are timed incor-
rectly when LH kits alone are used to time IUI [38] and
some women may even ovulate before LH can be detected
in the urine [39]. In addition, the small size of the study
may have limited the detection of a small but significant
difference in outcome.
In a prospective, randomized, cross-over study that evalu-
ated the benefit of hCG-timed versus LH-timed IUI in CC
stimulated cycles [40], no statistically significant differ-
ence was seen in the pregnancy rate with the use of hCG
(4.2%) versus LH monitoring (4.3%). The low pregnancy
rat in this study suggests a different patient population to
ours and such low pregnancy rate may have masked a dif-
ference in the two timing approaches.
Conclusions
The findings of this study support the practice of adminis-
tering hCG to trigger ovulation and time insemination
and to time its administration according to LH-surge.
Waiting for LH-surge to happen before giving hCG might
be associated with high pregnancy rates when CC is used
(whether alone or in combination with gonadotropins).
On the other hand, with FSH treatment the occurrence of
LH-surge before administering hCG might be associated
with lower pregnancy rates. It is important to mention
that the retrospective design of our study may bias the
results. A retrospective study is less likely to have clearly
defined criteria for patient inclusion, and non-rand-
omized trials have the potential to provide a distorted
view of the problem. However, the large number of treat-
ment cycles (2000 cycles) and the absence of significant
difference in relevant confounding factors (age, fertility
diagnosis and duration) among the study groups would
allow drawing useful conclusions that consitiute the basis
for future randomized trials. A prospective clinical trial in
which the method for timing insemination is randomly
determined before starting ovarian stimulation would
help in achieving unequivocal conclusions.
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